Metabolic Effects of Tirzepatide and Semaglutide: Energy Expenditure and Adaptations During and After Treatment
Background & aim: Obesity pharmacotherapy has significantly improved weight management, with semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1 and GIP receptor agonist) demonstrating substantial efficacy in reducing body weight. These drugs primarily act by suppressing appetite and improving glucose…
Comparative anti-fibrotic efficacy of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & aim: Resmetirom (RES, THR-βR agonist) has recently been FDA-approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other drug concepts are in late-stage clinical development for MASH, including semaglutide (SEMA, GLP1R agonist), tirzepatide (TZP, GLP1R-GIPR co-agonist) and efruxifermin…
Reproducible efficacy and clinical translatability of longer-term semaglutide treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & aim: The glucagon-like peptide-1 (GLP-1) analogue semaglutide has been reported to promote resolution of MASH and improve fibrosis stage in a recent clinical phase 3 trial (ESSENCE, Sanyal et al., NEJM; 2025). The present study aimed to evaluate…
